Figure 3. Anti-CCL28 inhibits IgA ASC homing to the mammary gland and IgA antibody accumulation in the milk. (A) Tissue sections from the mammary gland of 9-d postpartum mice treated with anti-CCL28 function-blocking antibody or isotype control antibody. Tissue sections were stained with anti-IgA (green) and anti–TCR-β (red) antibodies. The subiliac lymph node is included in the top region of each photograph as a reference point. A magnification of 200. (B) Milk was collected on days 1 and 9 postpartum from mice treated with anti-CCL28 or isotype control antibody. IgA, IgG1, and IgM levels in the milk were determined. Horizontal bars represent the average of each group. Differences between IgA ASCs and IgA antibody accumulation between control and anti-CCL28 treatment groups were statistically significant (P < 0.001).
Figure 3. Anti-CCL28 inhibits IgA ASC homing to the mammary gland and IgA antibody accumulation in the milk. (A) Tissue sections from the mammary gland of 9-d postpartum mice treated with anti-CCL28 function-blocking antibody or isotype control antibody. Tissue sections were stained with anti-IgA (green) and anti–TCR-β (red) antibodies. The subiliac lymph node is included in the top region of each photograph as a reference point. A magnification of 200. (B) Milk was collected on days 1 and 9 postpartum from mice treated with anti-CCL28 or isotype control antibody. IgA, IgG1, and IgM levels in the milk were determined. Horizontal bars represent the average of each group. Differences between IgA ASCs and IgA antibody accumulation between control and anti-CCL28 treatment groups were statistically significant (P < 0.001).
